Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Conformis enters license agreement with Paragon 28 » 16:32
04/19/21
04/19
16:32
04/19/21
16:32
CFMS

Conformis

/

+

Conformis announced that…

Conformis announced that it has entered into a license agreement with Paragon 28, granting Paragon 28 a non-exclusive license under a subset of Conformis' U.S. patents for the use of patient-specific instruments with off-the-shelf implants in Paragon 28's APEX 3D total ankle replacement system. "We are pleased to reach this agreement with Paragon 28, enabling it to incorporate our patient-specific instrument technology in its anticipated total ankle replacement offering," said Mark Augusti, president and CEO. "We believe that this latest license agreement further demonstrates the broad applicability and clinical appeal of Conformis' technology."

ShowHide Related Items >><<
CFMS Conformis
/

+

CFMS Conformis
/

+

03/04/21 Canaccord
Conformis undervalued despite momentum, says Canaccord
CFMS Conformis
/

+

  • 12
    Feb
  • 24
    Sep
CFMS Conformis
/

+

Over a month ago
Hot Stocks
Conformis announces data from review of Conformis iTotal knee replacement tech » 07:15
03/16/21
03/16
07:15
03/16/21
07:15
CFMS

Conformis

$1.13 /

+0.1 (+9.71%)

Conformis announced that…

Conformis announced that an independent, retrospective review of hospital data has concluded that Conformis iTotal knee replacement technology is more cost-effective than leading traditional, off-the-shelf implants. Importantly, this study was independently performed with no sponsorship or funding from Conformis. The new abstract was presented by authors at the Orthopaedic Research Society 2021 Annual Meeting, held in February 2021: Custom-designed total knee arthroplasty is cost-effective in comparison to a standard implant, Navin Fernando MD, Ann Chancellor CCRC, Paul Manner MD, University of Washington, Seattle, WA, 2021 Proceedings of Orthopaedic Research Society, Paper 0980. The retrospective review was performed at a single medical institution between 2016 and 2019 using a financial database and electronic health records. Patient demographics, total direct costs, length of stay and opioid use were all investigated. Two groups were evaluated for procedures performed by a single surgeon, Dr. Paul Manner, MD, Joint Replacement/Hip and Knee Arthritis Professor in the Department of Orthopaedics and Sports Medicine at the University of Washington in Seattle. Procedures for a control group were performed by a second surgeon, Dr. Navin Fernando: Primary group - patient-specific implant; Comparison group - traditional implant; Control group - traditional implant performed by second surgeon. The median patient age was 66 years old, and the median BMI was 31 for the three groups. Mean LOS analysis: 1.35 days for Conformis iTotal patients; 1.99 days for Zimmer Persona patients; 1.83 for Stryker Triathlon patients. Total direct costs analysis: $9,341 for Conformis iTotal patients; $10,347 for Zimmer Persona patients; $10,604 for Stryker Triathlon patients. There was no apparent difference in morphine equivalent dose use amongst the three groups.. The study concludes that total direct costs for hospital admissions appear to be more cost-effective with the Conformis iTotal System, and variables such as operative time and LOS also appear to favor a patient-specific implant over traditional, off-the-shelf implants. Three other comparative studies published between 2017 and 2019 also demonstrate that Conformis iTotal implants drive savings for hospitals and insurance companies.

ShowHide Related Items >><<
CFMS Conformis
$1.13 /

+0.1 (+9.71%)

CFMS Conformis
$1.13 /

+0.1 (+9.71%)

03/04/21 Canaccord
Conformis undervalued despite momentum, says Canaccord
CFMS Conformis
$1.13 /

+0.1 (+9.71%)

  • 12
    Feb
  • 24
    Sep
CFMS Conformis
$1.13 /

+0.1 (+9.71%)

Recommendations
Conformis undervalued despite momentum, says Canaccord » 07:58
03/04/21
03/04
07:58
03/04/21
07:58
CFMS

Conformis

$1.09 /

-0.095 (-8.05%)

Canaccord analyst Kyle…

Canaccord analyst Kyle Rose believes Conformis shares remain undervalued despite its year-to-date momentum. He said in the latest quarter the company executed on key R&D programs, and the recent capital raise provides an ample war chest to backstop near-term commercial volatility. Rose reiterated his Buy rating and $2 price target on Conformis shares.

ShowHide Related Items >><<
CFMS Conformis
$1.09 /

-0.095 (-8.05%)

CFMS Conformis
$1.09 /

-0.095 (-8.05%)

  • 12
    Feb
  • 24
    Sep
CFMS Conformis
$1.09 /

-0.095 (-8.05%)

On The Fly
Fly Intel: After-Hours Movers » 18:40
03/03/21
03/03
18:40
03/03/21
18:40
AEO

American Eagle

$25.51 /

+0.435 (+1.73%)

, RMNI

Rimini Street

$8.72 /

+0.07 (+0.81%)

, SPLK

Splunk

$143.31 /

-5.69 (-3.82%)

, HRTG

Heritage Insurance

$10.30 /

+0.1 (+0.98%)

, SBOW

SilverBow Resources

$8.46 /

+0.19 (+2.30%)

, SNOW

Snowflake

$246.86 /

-23.73 (-8.77%)

, KNSA

Kiniksa

$21.78 /

+0.43 (+2.01%)

, YEXT

Yext

$16.55 /

-1.16 (-6.55%)

, VRM

Vroom

$43.92 /

-3.93 (-8.21%)

, OKTA

Okta

$242.42 /

-16.595 (-6.41%)

, AES

AES Corp.

$26.89 /

+0.07 (+0.26%)

, MRVL

Marvell

$45.47 /

-2.33 (-4.87%)

, CFMS

Conformis

$1.09 /

-0.095 (-8.05%)

, RADA

Rada Electronic

$12.38 /

-0.52 (-4.03%)

, LASR

nLight

$36.79 /

-0.93 (-2.47%)

Check out this evening's…

ShowHide Related Items >><<
YEXT Yext
$16.55 /

-1.16 (-6.55%)

VRM Vroom
$43.92 /

-3.93 (-8.21%)

SPLK Splunk
$143.31 /

-5.69 (-3.82%)

SNOW Snowflake
$246.86 /

-23.73 (-8.77%)

SBOW SilverBow Resources
$8.46 /

+0.19 (+2.30%)

RMNI Rimini Street
$8.72 /

+0.07 (+0.81%)

RADA Rada Electronic
$12.38 /

-0.52 (-4.03%)

OKTA Okta
$242.42 /

-16.595 (-6.41%)

MRVL Marvell
$45.47 /

-2.33 (-4.87%)

KNSA Kiniksa
$21.78 /

+0.43 (+2.01%)

HRTG Heritage Insurance
$10.30 /

+0.1 (+0.98%)

CFMS Conformis
$1.09 /

-0.095 (-8.05%)

AES AES Corp.
$26.89 /

+0.07 (+0.26%)

AEO American Eagle
$25.51 /

+0.435 (+1.73%)

AEO American Eagle
$25.51 /

+0.435 (+1.73%)

02/24/21 Cowen
American Eagle upgraded to Outperform from Market Perform at Cowen
02/24/21 Cowen
American Eagle upgraded to Outperform from Market Perform at Cowen
01/25/21 RBC Capital
American Eagle upgraded to Outperform from Sector Perform at RBC Capital
01/25/21 RBC Capital
American Eagle upgraded to Outperform from Sector Perform at RBC Capital
RMNI Rimini Street
$8.72 /

+0.07 (+0.81%)

02/02/21 Craig-Hallum
Rimini Street price target raised to $11 from $6 at Craig-Hallum
02/02/21 Roth Capital
Rimini Street price target raised to $15 from $10 at Roth Capital
02/02/21 Alliance Global Partners
Rimini Street price target raised to $10 from $7.50 at Alliance Global Partners
10/02/20 Craig-Hallum
Rimini Street initiated with a Buy at Craig-Hallum
SPLK Splunk
$143.31 /

-5.69 (-3.82%)

03/03/21 Citi
Splunk assumed with a Neutral at Citi
03/02/21 RBC Capital
Splunk may see 'slight upside' in Q4 results, says RBC Capital
02/24/21 Jefferies
Jefferies remains a buyer of Splunk, sees 'favorable set-up' into earnings
02/17/21 Mizuho
Splunk price target raised to $190 from $180 at Mizuho
HRTG Heritage Insurance
$10.30 /

+0.1 (+0.98%)

11/04/20 Truist
Heritage Insurance price target lowered to $14 from $19 at Truist
10/09/20 Sidoti
Heritage Insurance initiated with a Buy at Sidoti
04/06/20 Piper Sandler
Heritage Insurance upgraded to Overweight from Neutral at Piper Sandler
SBOW SilverBow Resources
$8.46 /

+0.19 (+2.30%)

05/14/20 Northland
Northland upgrades SilverBow to Outperform on natural gas shift
05/14/20 Northland
SilverBow Resources upgraded to Outperform from Market Perform at Northland
03/13/20 Northland
SilverBow Resources downgraded to Market Perform from Outperform at Northland
SNOW Snowflake
$246.86 /

-23.73 (-8.77%)

01/21/21 Goldman Sachs
Snowflake initiated with a Neutral at Goldman Sachs
01/19/21 Rosenblatt
Snowflake initiated with a Neutral at Rosenblatt
01/15/21 Credit Suisse
Snowflake price target raised to $310 from $265 at Credit Suisse
01/13/21 Citi
Snowflake price target raised to $325 from $300 at Citi
KNSA Kiniksa
$21.78 /

+0.43 (+2.01%)

11/24/20 Evercore ISI
Kiniksa initiated with an Outperform at Evercore ISI
10/06/20 Goldman Sachs
Goldman reiterates $34 target on Kiniksa after 'impressive' data
07/17/20 JPMorgan
Kiniksa risk/reward attractive into Phase 2 data, says JPMorgan
06/29/20 Goldman Sachs
Kiniksa price target raised to $33 from $29 at Goldman Sachs
YEXT Yext
$16.55 /

-1.16 (-6.55%)

12/04/20 DA Davidson
Yext price target lowered to $20.50 from $22 at DA Davidson
12/04/20 Truist
Yext growth should pick up next year, says Truist
07/09/20 Needham
Yext price target raised to $21 from $19 at Needham
06/25/20 MKM Partners
Yext initiated with a Buy at MKM Partners
VRM Vroom
$43.92 /

-3.93 (-8.21%)

02/24/21 Jefferies
Carvana well positioned for 'beat/raise' earnings report, says Jefferies
02/16/21 Wells Fargo
Vroom price target raised to $60 from $55 at Wells Fargo
01/05/21 Stifel
Stifel adds Vroom to Select List, removes Buy-rated Peloton
12/17/20
Fly Intel: Top five analyst initiations
OKTA Okta
$242.42 /

-16.595 (-6.41%)

03/02/21 RBC Capital
Okta price target raised to $300 from $264 at RBC Capital
02/23/21 Deutsche Bank
Okta initiated with a Buy at Deutsche Bank
02/17/21 Mizuho
Okta price target raised to $305 from $270 at Mizuho
02/16/21 Canaccord
Okta price target raised to $300 from $250 at Canaccord
AES AES Corp.
$26.89 /

+0.07 (+0.26%)

01/11/21 BofA
BofA US 1 List changes
09/18/20 Morgan Stanley
AES Corp. price target raised to $23.50 from $19 at Morgan Stanley
08/13/20 BofA
AES Corp. added to US 1 List; Ameren removed at BofA
05/20/20 Seaport Global
Seaport Global starts power and competitive retail sector with positive outlook
MRVL Marvell
$45.47 /

-2.33 (-4.87%)

03/02/21 Susquehanna
Marvell results expected to be a modest beat, says Susquehanna
02/16/21 Needham
Inphi price target raised to $191 from $175 at Needham
02/09/21 Barclays
Inphi downgraded to Equal Weight on Marvell deal at Barclays
01/26/21 Barclays
Marvell price target raised to $60 from $50 at Barclays
CFMS Conformis
$1.09 /

-0.095 (-8.05%)

RADA Rada Electronic
$12.38 /

-0.52 (-4.03%)

02/10/21 Alliance Global Partners
Rada Electronic price target raised to $19 from $14 at Alliance Global Partners
12/22/20 Alliance Global Partners
Rada Electronic price target raised to $14 from $13 at Alliance Global Partners
12/18/20 Alliance Global Partners
Rada Electronic price target raised to $13 from $12 at Alliance Global Partners
LASR nLight
$36.79 /

-0.93 (-2.47%)

02/18/21 DA Davidson
nLight price target raised to $48 from $30 at DA Davidson
02/18/21 Craig-Hallum
nLight price target raised to $48 from $32 at Craig-Hallum
02/18/21 Canaccord
nLight price target raised to $53 from $27 at Canaccord
01/21/21 Berenberg
nLight assumed with a Hold at Berenberg
YEXT Yext
$16.55 /

-1.16 (-6.55%)

VRM Vroom
$43.92 /

-3.93 (-8.21%)

SPLK Splunk
$143.31 /

-5.69 (-3.82%)

SNOW Snowflake
$246.86 /

-23.73 (-8.77%)

SBOW SilverBow Resources
$8.46 /

+0.19 (+2.30%)

RMNI Rimini Street
$8.72 /

+0.07 (+0.81%)

RADA Rada Electronic
$12.38 /

-0.52 (-4.03%)

OKTA Okta
$242.42 /

-16.595 (-6.41%)

MRVL Marvell
$45.47 /

-2.33 (-4.87%)

LASR nLight
$36.79 /

-0.93 (-2.47%)

KNSA Kiniksa
$21.78 /

+0.43 (+2.01%)

HRTG Heritage Insurance
$10.30 /

+0.1 (+0.98%)

CFMS Conformis
$1.09 /

-0.095 (-8.05%)

AES AES Corp.
$26.89 /

+0.07 (+0.26%)

AEO American Eagle
$25.51 /

+0.435 (+1.73%)

  • 04
    Mar
  • 12
    Feb
  • 07
    Dec
  • 24
    Sep
  • 16
    Sep
  • 11
    Sep
  • 14
    Aug
  • 22
    Jul
  • 09
    Jun
  • 14
    May
SPLK Splunk
$143.31 /

-5.69 (-3.82%)

SNOW Snowflake
$246.86 /

-23.73 (-8.77%)

MRVL Marvell
$45.47 /

-2.33 (-4.87%)

AEO American Eagle
$25.51 /

+0.435 (+1.73%)

YEXT Yext
$16.55 /

-1.16 (-6.55%)

VRM Vroom
$43.92 /

-3.93 (-8.21%)

SPLK Splunk
$143.31 /

-5.69 (-3.82%)

SNOW Snowflake
$246.86 /

-23.73 (-8.77%)

RMNI Rimini Street
$8.72 /

+0.07 (+0.81%)

OKTA Okta
$242.42 /

-16.595 (-6.41%)

MRVL Marvell
$45.47 /

-2.33 (-4.87%)

KNSA Kiniksa
$21.78 /

+0.43 (+2.01%)

HRTG Heritage Insurance
$10.30 /

+0.1 (+0.98%)

CFMS Conformis
$1.09 /

-0.095 (-8.05%)

AEO American Eagle
$25.51 /

+0.435 (+1.73%)

VRM Vroom
$43.92 /

-3.93 (-8.21%)

SPLK Splunk
$143.31 /

-5.69 (-3.82%)

SNOW Snowflake
$246.86 /

-23.73 (-8.77%)

RMNI Rimini Street
$8.72 /

+0.07 (+0.81%)

OKTA Okta
$242.42 /

-16.595 (-6.41%)

MRVL Marvell
$45.47 /

-2.33 (-4.87%)

AES AES Corp.
$26.89 /

+0.07 (+0.26%)

AEO American Eagle
$25.51 /

+0.435 (+1.73%)

Hot Stocks
Conformis sees Q1 product revenue $13M-$14M » 16:15
03/03/21
03/03
16:15
03/03/21
16:15
CFMS

Conformis

$1.09 /

-0.095 (-8.05%)

Historically, we see a…

Historically, we see a drop in first quarter revenue compared to the preceding fourth quarter as many health plans reset on January 1. In addition, we have continued to experience pressure on our business from reduced elective procedures into 2021. Accordingly, we expect our first quarter product revenue to be in the range of $13.0 million to $14.0 million. We believe this pressure will continue through the second quarter, but that we may see elective volumes improve in the third quarter as vaccines become more widely available.

ShowHide Related Items >><<
CFMS Conformis
$1.09 /

-0.095 (-8.05%)

CFMS Conformis
$1.09 /

-0.095 (-8.05%)

  • 12
    Feb
  • 24
    Sep
CFMS Conformis
$1.09 /

-0.095 (-8.05%)

Earnings
Conformis reports Q4 EPS (8c), consensus (10c) » 16:14
03/03/21
03/03
16:14
03/03/21
16:14
CFMS

Conformis

$1.09 /

-0.095 (-8.05%)

Reports Q4 revenue…

Reports Q4 revenue $16.7M, consensus $17.68M. "Though the COVID-19 pandemic continues to create uncertainty in orthopedic procedure levels, Conformis has remained committed to the continuation of our new product development schedule. As such, we expect 2021 to be an exciting year in regards to new product offerings, especially our new total knee system. While this system can be used in the in-patient and out-patient settings, we are particularly focused on the ambulatory care setting," said Mark Augusti, President and Chief Executive Officer. "Our recently completed $85 million capital raise gives us the flexibility to drive our growth strategy."

ShowHide Related Items >><<
CFMS Conformis
$1.09 /

-0.095 (-8.05%)

CFMS Conformis
$1.09 /

-0.095 (-8.05%)

  • 12
    Feb
  • 24
    Sep
CFMS Conformis
$1.09 /

-0.095 (-8.05%)

Hot Stocks
Conformis granted 510k FDA clearance for iTotal Identity knee replacement system » 09:35
02/22/21
02/22
09:35
02/22/21
09:35
CFMS

Conformis

$1.07 /

-0.04 (-3.62%)

Conformis has been grated…

Conformis has been grated 510k FDA clearance for its iTotal Identity Cruciate Retaining Knee Replacement System and iTotal Identity Posterior Stabilizing Knee Replacement System, the FDA said on its website. Reference Link

ShowHide Related Items >><<
CFMS Conformis
$1.07 /

-0.04 (-3.62%)

CFMS Conformis
$1.07 /

-0.04 (-3.62%)

  • 12
    Feb
  • 24
    Sep
CFMS Conformis
$1.07 /

-0.04 (-3.62%)

Syndicate
Conformis 81M share Spot Secondary priced at $1.05 » 08:35
02/12/21
02/12
08:35
02/12/21
08:35
CFMS

Conformis

$1.35 /

+0.04 (+3.05%)

The deal size was…

The deal size was increased to $85M in common stock from $40M in common stock. Oppenheimer acted as sole book running manager for the offering.

ShowHide Related Items >><<
CFMS Conformis
$1.35 /

+0.04 (+3.05%)

CFMS Conformis
$1.35 /

+0.04 (+3.05%)

  • 12
    Feb
  • 24
    Sep
CFMS Conformis
$1.35 /

+0.04 (+3.05%)

Syndicate
Conformis announces common stock offering, no amount given » 16:06
02/11/21
02/11
16:06
02/11/21
16:06
CFMS

Conformis

$1.35 /

+0.04 (+3.05%)

Conformis announced that…

Conformis announced that it intends to offer shares of its common stock in an underwritten public offering. Conformis intends to use the net proceeds of the offering for general corporate purposes, which may include research and development costs, sales and marketing costs, clinical studies, manufacturing development, the acquisition or licensing of other businesses or technologies, repayment and refinancing of debt, working capital and capital expenditures. Oppenheimer & Co. is acting as the sole book-running manager for the offering.

ShowHide Related Items >><<
CFMS Conformis
$1.35 /

+0.04 (+3.05%)

CFMS Conformis
$1.35 /

+0.04 (+3.05%)

  • 24
    Sep
CFMS Conformis
$1.35 /

+0.04 (+3.05%)

On The Fly
Fly Intel: Pre-market Movers » 08:55
01/22/21
01/22
08:55
01/22/21
08:55
ADMP

Adamis Pharmaceuticals

$1.26 /

-0.17 (-11.89%)

, CFMS

Conformis

$1.39 /

+0.165 (+13.47%)

, RF

Regions Financial

$17.81 /

-0.33 (-1.82%)

, ALLY

Ally Financial

$39.93 /

-1.43 (-3.46%)

, FHN

First Horizon

$14.34 /

-0.36 (-2.45%)

, SLB

Schlumberger

$24.18 /

-1.16 (-4.58%)

, HBAN

Huntington Bancshares

$14.51 /

-0.18 (-1.23%)

, IBM

IBM

$131.80 /

+1.72 (+1.32%)

, PPG

PPG

$143.94 /

-0.635 (-0.44%)

, SENS

Senseonics

$2.42 /

-0.245 (-9.21%)

, INTC

Intel

$62.47 /

+3.81 (+6.50%)

Check out this morning's…

ShowHide Related Items >><<
SLB Schlumberger
$24.18 /

-1.16 (-4.58%)

SENS Senseonics
$2.42 /

-0.245 (-9.21%)

RF Regions Financial
$17.81 /

-0.33 (-1.82%)

PPG PPG
$143.94 /

-0.635 (-0.44%)

INTC Intel
$62.47 /

+3.81 (+6.50%)

IBM IBM
$131.80 /

+1.72 (+1.32%)

HBAN Huntington Bancshares
$14.51 /

-0.18 (-1.23%)

FHN First Horizon
$14.34 /

-0.36 (-2.45%)

CFMS Conformis
$1.39 /

+0.165 (+13.47%)

ALLY Ally Financial
$39.93 /

-1.43 (-3.46%)

ADMP Adamis Pharmaceuticals
$1.26 /

-0.17 (-11.89%)

ADMP Adamis Pharmaceuticals
$1.26 /

-0.17 (-11.89%)

11/17/20
Adamis Pharmaceuticals cut to Hold at Maxim after Zimhi CRL from FDA
11/16/20 Maxim
Adamis Pharmaceuticals downgraded to Hold from Buy at Maxim
05/13/20 Maxim
Adamis Pharmaceuticals upgraded to Buy from Hold at Maxim
05/13/20 Maxim
Adamis Pharmaceuticals upgraded to Buy from Hold at Maxim
CFMS Conformis
$1.39 /

+0.165 (+13.47%)

RF Regions Financial
$17.81 /

-0.33 (-1.82%)

01/15/21 Compass Point
Regions Financial upgraded to Buy from Neutral at Compass Point
01/12/21 UBS
UBS downgrades Citizens on revenue headwinds, Wells new top pick
01/07/21 Keefe Bruyette
Regions Financial upgraded to Outperform from Market Perform at Keefe Bruyette
01/07/21 Baird
Regions Financial downgraded to Neutral from Outperform at Baird
ALLY Ally Financial
$39.93 /

-1.43 (-3.46%)

01/19/21 JPMorgan
Ally Financial price target raised to $47 from $32 at JPMorgan
01/13/21 Janney Montgomery Scott
Ally Financial price target raised to $45 from $40 at Janney Montgomery Scott
01/13/21 Credit Suisse
Ally Financial price target raised to $42 from $34 at Credit Suisse
01/13/21 Citi
Ally Financial price target raised to $45 from $33 at Citi
FHN First Horizon
$14.34 /

-0.36 (-2.45%)

10/08/20 Jefferies
First Horizon upgraded to Buy from Hold at Jefferies
09/22/20 Raymond James
First Horizon upgraded to Strong Buy from Outperform at Raymond James
08/20/20 Goldman Sachs
First Horizon reinstated with a Buy at Goldman Sachs
08/17/20 Morgan Stanley
First Horizon resumed with an Equal Weight at Morgan Stanley
SLB Schlumberger
$24.18 /

-1.16 (-4.58%)

12/18/20 JPMorgan
Schlumberger price target raised to $21 from $19 at JPMorgan
12/15/20 Citi
Schlumberger price target raised to $30 from $25 at Citi
12/10/20 HSBC
Schlumberger downgraded to Reduce from Hold at HSBC
11/30/20 Susquehanna
Susquehanna raises targets across Oilfield Services on cyclical rebound
HBAN Huntington Bancshares
$14.51 /

-0.18 (-1.23%)

01/13/21 Piper Sandler
PNC Financial downgraded to Neutral from Overweight at Piper Sandler
01/06/21 Wedbush
Huntington Bancshares added to Best Ideas List at Wedbush
01/06/21 Deutsche Bank
Huntington Bancshares price target raised to $14 from $10.50 at Deutsche Bank
01/05/21 Piper Sandler
TCF Financial upgraded to Overweight from Neutral at Piper Sandler
IBM IBM
$131.80 /

+1.72 (+1.32%)

01/22/21 Morgan Stanley
IBM miss in software elevates concerns, says Morgan Stanley
10/20/20 Morgan Stanley
Morgan Stanley continues to view IBM as 'a 2022 stock'
10/20/20 Citi
IBM is 'getting even more complex,' says Citi
10/20/20 BMO Capital
IBM price target lowered to $138 from $140 at BMO Capital
PPG PPG
$143.94 /

-0.635 (-0.44%)

01/20/21 Citi
Citi adds PPG to US Focus List, removes FMC
01/14/21 Berenberg
PPG upgraded to Buy with $165 price target at Berenberg
01/14/21 Berenberg
PPG upgraded to Buy from Hold at Berenberg
12/01/20 Deutsche Bank
PPG price target raised to $165 from $155 at Deutsche Bank
SENS Senseonics
$2.42 /

-0.245 (-9.21%)

01/20/21 BTIG
BTIG cuts Senseonics to Neutral, sees no fundamental reason for rapid rise
01/20/21 BTIG
Senseonics downgraded to Neutral from Buy at BTIG
01/20/21 Craig-Hallum
Senseonics downgraded to Sell at Craig-Hallum
01/20/21 Craig-Hallum
Senseonics downgraded to Sell from Hold at Craig-Hallum
INTC Intel
$62.47 /

+3.81 (+6.50%)

01/22/21 Morgan Stanley
Intel price target raised to $72 after 'very strong quarter' at Morgan Stanley
01/22/21 Roth Capital
Intel price target raised to $60 from $50 at Roth Capital
01/22/21 Northland
Intel price target raised to $57 from $46 at Northland
01/22/21 BMO Capital
Intel price target raised to $75 from $70 at BMO Capital
SLB Schlumberger
$24.18 /

-1.16 (-4.58%)

SENS Senseonics
$2.42 /

-0.245 (-9.21%)

RF Regions Financial
$17.81 /

-0.33 (-1.82%)

PPG PPG
$143.94 /

-0.635 (-0.44%)

INTC Intel
$62.47 /

+3.81 (+6.50%)

IBM IBM
$131.80 /

+1.72 (+1.32%)

HBAN Huntington Bancshares
$14.51 /

-0.18 (-1.23%)

FHN First Horizon
$14.34 /

-0.36 (-2.45%)

CFMS Conformis
$1.39 /

+0.165 (+13.47%)

ALLY Ally Financial
$39.93 /

-1.43 (-3.46%)

  • 22
    Jan
  • 24
    Sep
  • 18
    Sep
SLB Schlumberger
$24.18 /

-1.16 (-4.58%)

RF Regions Financial
$17.81 /

-0.33 (-1.82%)

INTC Intel
$62.47 /

+3.81 (+6.50%)

IBM IBM
$131.80 /

+1.72 (+1.32%)

HBAN Huntington Bancshares
$14.51 /

-0.18 (-1.23%)

SLB Schlumberger
$24.18 /

-1.16 (-4.58%)

SENS Senseonics
$2.42 /

-0.245 (-9.21%)

RF Regions Financial
$17.81 /

-0.33 (-1.82%)

PPG PPG
$143.94 /

-0.635 (-0.44%)

INTC Intel
$62.47 /

+3.81 (+6.50%)

IBM IBM
$131.80 /

+1.72 (+1.32%)

HBAN Huntington Bancshares
$14.51 /

-0.18 (-1.23%)

FHN First Horizon
$14.34 /

-0.36 (-2.45%)

ALLY Ally Financial
$39.93 /

-1.43 (-3.46%)

SLB Schlumberger
$24.18 /

-1.16 (-4.58%)

SENS Senseonics
$2.42 /

-0.245 (-9.21%)

RF Regions Financial
$17.81 /

-0.33 (-1.82%)

PPG PPG
$143.94 /

-0.635 (-0.44%)

INTC Intel
$62.47 /

+3.81 (+6.50%)

IBM IBM
$131.80 /

+1.72 (+1.32%)

FHN First Horizon
$14.34 /

-0.36 (-2.45%)

ALLY Ally Financial
$39.93 /

-1.43 (-3.46%)

ADMP Adamis Pharmaceuticals
$1.26 /

-0.17 (-11.89%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.